Furthermore, we discovered that a small‐molecule inhibitor, UNC6934, inhibited the histone modification of NSD2, thereby blocking the ERN1–JNK axis and alleviating NSD2‐induced intestinal barrier impairment and NASH progression in HFCD‐fed mice. Here, NSD2 is linked to metabolic dysfunction-associated steatohepatitis.